A Novel Druggable Epigenetic Vulnerability Pathway in HCC
Description: PROJECT NARRATIVE Nearly 29,000 Americans die from hepatocellular (liver) carcinoma (HCC) every year and current treatments for HCC provide no long-term benefit, highlighting the urgent need for new and effective therapies. We have discovered that a protein called CLK1 is required for the growth of HCC tumors, and found that inhibiting CLK1 not only blocks HCC tumor growth but also enhances the ability of the immune system to destroy the tumor. The results of the experiments proposed in this application will establish CLK1 as a novel drug target for the development of new and effective HCC therapies.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2018-04-01
End date: 2024-03-31
Investigator: MICHELLE ALICE KELLIHER
Institution: UNIV OF MASSACHUSETTS MED SCH WORCESTER
Funded outputs count: 19
Funder award ID: R01CA218008
OpenAlex ID: G7398190871